Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides

Summary

Open-label single center study. Patients will be divided in four groups of 7. Group 1: 8 melanoma-specific peptides in saline; Group 2: same mix of peptides + Montanide ISA51; Group 3: same mix of peptides + IMP321 500 µg; Group 4: same mix of peptides + IMP321 500 µg + Montanide ISA51. These vaccines will be administered every 3 weeks on 5 occasions by intradermal and superficial subcutaneous injections.

Timeline

Start

2006-08

Primary completion

2013-12-13

Completion

2013-12-13

Drugs

Indications